Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zorifertinib plus radiotherapy as first-line treatment in EGFR-mutant NSCLC with brain metastases
ChiCTR2600121513Phase 4Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zorifertinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by Chongqing University Cancer Hospital. Primary endpoint: Intracranial Progression-Free Survival. Started Mar 2026; status: recruiting.
02
Drugs
zorifertinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on ChiCTR2600121513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121513.